^(89)Sr及^(89)Sr联合唑来膦酸治疗多发骨转移癌的对照研究  

Efects of Strontium-89 combined with Zoledronic acid for bone metastases

作　　者：袁彬 陈晓泉 许建林 杨琪 蒋喆 施常备 

机构地区：[1]陕西省肿瘤医院,陕西西安710061

出　　处：《现代肿瘤医学》2013年第3期610-612,共3页Journal of Modern Oncology

摘　　要：目的:探讨89Sr及89Sr联合唑来膦酸治疗多发骨转移癌的临床疗效。方法:64例多发骨转移癌患者随机分为89Sr治疗组(单纯组)和89Sr联合唑来膦酸(联合组)各32例,观察镇痛疗效、骨转移病灶及治疗过程中毒副反应。结果:疼痛缓解率:单纯组81.2%,联合组90.6%,骨病灶缓解率:单纯组75%,联合组87.5%。联合组优于单纯组,毒副作用无叠加。结论:对于多发骨转移癌的患者两种治疗方法均有较好的疗效,联合组更优,可重复给药,安全性高,明显提高患者的生存质量。Objective： To compare the clinical effects of S9Sr combined Zoledronic acid as a palliative therapy method for cancer patients with bone metastases. Methods： Total of 64 patients with bone metastases were randomly divided into two groups, treated with S9Sr（pure group） and SgSr combined Zoledronic acid（experimental group）. Re- suits： In the pure group and experimental group effective rates were 81.2% and 90.6%. Bone relief rates were 75% and 87.5%. No obvious side -effect was found. Conclusion： The total effect rate of two groups. The effect of the ex- periment group is obvious,and could be used repeatedly. IVs safe for patients and could improve life quality of pa- tients.

关 键 词：89Sr核素 唑来膦酸 多发骨转移癌 

分 类 号：R739.42[医药卫生—肿瘤]